|
Three consecutive years of sales and operating profit growth
2015.03.06
|
|---|
|
- Sales up 26.9% and operating profit up 32.6% year-on-year - Expansion of injectable product line and completion of production facilities for animal cell culture media - Exports to Russia up 47%
Daehan New Pharm continues its strong growth trend. In 2014, the company achieved sales of 71.94 billion KRW, a 26.9% increase from the previous year, and operating profit of 7.91 billion KRW, up 32.6%, marking its third consecutive year of remarkable growth.
Furthermore, as cash flow-oriented management became established across all departments, borrowings and accounts receivable decreased, leading to an improved financial structure.
Daehan New Pharm operates three key business divisions: the pharmaceutical business (its core segment), the veterinary medicine business (its foundational segment), and the bio business, which is being driven as a future growth engine. All divisions achieved double-digit growth last year, making it a significant year for the company.
In the pharmaceutical business, strong performance was driven by continuous growth and market leadership in the “Well-being” division through The Only Product strategy, innovation in distribution channels by directly managing hospitals and clinics, and strengthening the distribution network through customer asset acquisition. Ongoing new product launches created an optimized portfolio, enhancing sales synergy. The company also improved organizational productivity and internal capabilities through talent management that fosters and develops core professionals.
Export performance in pharmaceuticals has also been notable. Overseas exports, a source of pride for Daehan New Pharm, have steadily grown. In 2014, exports exceeded 10 billion KRW, with exports to Russia alone reaching USD 3.2 million — a 47% year-on-year increase for a single product.
The veterinary medicine business has strengthened customer satisfaction through customized product development and continues to cooperate with local governments and organizations to develop new products.
As for the bio business, regarded as the company’s future growth driver, Daehan New Pharm completed a new factory for animal cell culture media in April last year and began supplying domestically produced media from the third quarter. As the company gained recognition for quality following testing, its client base expanded. Through industry-academia collaboration, it is also engaging in R&D to introduce a new paradigm in cell proliferation. |


Home